<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897101</url>
  </required_header>
  <id_info>
    <org_study_id>639/2018/Sper/AOUFe</org_study_id>
    <nct_id>NCT03897101</nct_id>
  </id_info>
  <brief_title>Inflammation and Metabolic Acidosis at Birth (AGAIN: AutophaGy AcIdosis Newborn)</brief_title>
  <acronym>AGAIN</acronym>
  <official_title>Autophagy, Mitophagy, Inflammation and Plasmatic Concentration of Melatonin in Newborn With Metabolic Acidosis at Birth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Ferrara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AUSL Romagna Rimini</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital of Ferrara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protection of brain development is a major aim in the Neonatal Intensive Care Unit. Neonatal
      encephalopathy (NE) occurs in 1.8 to 7.7 infants per 1000 births. Over the last six years,
      several randomized control trials have demonstrated that therapeutic hypothermia reduces the
      rate of death or disability at 18 months of age among infants who survived. However, the
      neurodevelopmental outcome in milder NE not treated with hypothermia remains unclear.

      A multicenter prospective observational study will be conducted to determine biological
      changes of mild neonatal encephalopathy who are not recruited for therapeutic hypothermia .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a prospective observational multicenter study on 50 newborns with mild neonatal
      encephalopathy and metabolic acidosis at birth not qualified for therapeutic hypothermia
      compared to healthy controls.

      Infants with metabolic acidosis at birth and evidence of mild encephalopathy graded according
      to Sarnat&amp;Sarnat neurological evaluation will be recruited to evaluate plasma concentration
      of melatonin and levels of Autophagy, mitophagy and inflammation.

      Plasmatic changes will be compared to:

        -  healthy control

        -  infants with isolated metabolic acidosis at birth and normal neurological evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>7 Days</target_duration>
  <primary_outcome>
    <measure>change from baseline ATG5 Plasma concentration at 7 days of life</measure>
    <time_frame>birth, 72 hours, 7 days of life</time_frame>
    <description>correlation between metabolic acidosis at birth and Autophagy. ELISA test will be used to measure plasma levels of ATG5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline Parkin and Pink1 Plasma concentration at 7 days of life</measure>
    <time_frame>birth, 72 hours, 7 days of life</time_frame>
    <description>correlation between metabolic acidosis at birth and Mitophagy. ELISA test will be used to measure plasma levels of Parkin and Park1</description>
  </secondary_outcome>
  <other_outcome>
    <measure>change from baseline Plasma Concentration of Melatonin at 7 days of life</measure>
    <time_frame>birth, 72 hours, 7 days of life</time_frame>
    <description>UPLC-Massa Acquity-Xevo TQD (Waters) will be used to measure plasma melatonin concentration.</description>
  </other_outcome>
  <other_outcome>
    <measure>change from baseline of inflammatory cytokines at 7 days of life</measure>
    <time_frame>birth, 72 hours, 7 days of life</time_frame>
    <description>correlation between metabolic acidosis at birth and inflammatory cytokines. ELISA test will be used to measure plasma levels inflammatory cytokines.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Neonatal Encephalopathy</condition>
  <condition>Cell Damage</condition>
  <condition>Metabolic Acidosis</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>MILD NE</arm_group_label>
    <description>gestational age &gt; 35 weeks and weight &gt; 1800 gr
Apgar score &lt; 5 at 10 minutes o need for cardiopulmonary resuscitation at 10 minutes or evidence of base excess &gt; 12 mmol/L or pH &lt; 7,0 at initial blood gas analyses
evidence of mild encephalopathy graded according to Sarnat&amp;Sarnat neurological evaluation
normal amplitude integrated electroencephalography
Plasma levels of melatonin, Atg5, Parkin, Pink1, inflammatory cytokines will be evaluated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISOLATED METABOLIC ACIDOSIS</arm_group_label>
    <description>gestational age &gt; 35 weeks and weight &gt; 1800 gr
evidence of base excess &gt; 12 mmol/L or pH &lt; 7,0 at initial blood gas analyses
Normal Sarnat&amp;Sarnat neurological evaluation
Plasma levels of melatonin, Atg5, Parkin, Pink1, inflammatory cytokines will be evaluated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HEALTY CONTROLS</arm_group_label>
    <description>gestational age &gt; 35 weeks and weight &gt; 1800 gr Normal blood pH or base excess
Plasma levels of melatonin, Atg5, Parkin, Pink1, inflammatory cytokiness will be evaluated</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        will be recruited 50 newborns with mild neonatal encephalopathy and metabolic acidosis at
        birth not qualified for therapeutic hypothermia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  gestational age &gt; 35 weeks and weight &gt; 1800 gr

          -  Apgar score &lt; 5 at 10 minutes o need for cardiopulmonary resuscitation at 10 minutes
             or evidence of base excess &gt; 12 mmol/L or pH &lt; 7,0 at initial blood gas analyses

          -  evidence of mild encephalopathy graded according to Sarnat&amp;Sarnat neurological
             evaluation

          -  normal amplitude integrated electroencephalography

        Exclusion Criteria:

          -  suspected inborn errors of metabolism

          -  major chromosomal congenital defects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Hours</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Tarocco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital s. Anna Ferrara</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Tarocco, MD</last_name>
    <phone>+39 0532236014</phone>
    <email>anna.tarocco@unife.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paolo Pinton, Prof</last_name>
    <phone>0532455802</phone>
    <email>paolo.pinton@unife.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital &quot;Sant'Anna&quot; of Ferrara</name>
      <address>
        <city>Ferrara</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Tarocco, MD</last_name>
      <phone>+390532236014</phone>
      <email>anna.tarocco@unife.it</email>
    </contact>
    <contact_backup>
      <last_name>Paolo Pinton, Prof</last_name>
      <phone>+390532455802</phone>
      <email>paolo.pinton@unife.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Infermi Hospital Rimini</name>
      <address>
        <city>Rimini</city>
        <zip>47923</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Ancora, MD PhD</last_name>
      <phone>+390541705445</phone>
      <email>gina.ancora@auslromagna.it</email>
    </contact>
    <contact_backup>
      <last_name>Miria Natile, MD</last_name>
      <phone>+390541705445</phone>
      <email>mirianatile@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Alirezaei M, Kemball CC, Whitton JL. Autophagy, inflammation and neurodegenerative disease. Eur J Neurosci. 2011 Jan;33(2):197-204. doi: 10.1111/j.1460-9568.2010.07500.x. Epub 2010 Dec 7. Review.</citation>
    <PMID>21138487</PMID>
  </reference>
  <reference>
    <citation>Wang Q, Lv H, Lu L, Ren P, Li L. Neonatal hypoxic-ischemic encephalopathy: emerging therapeutic strategies based on pathophysiologic phases of the injury. J Matern Fetal Neonatal Med. 2019 Nov;32(21):3685-3692. doi: 10.1080/14767058.2018.1468881. Epub 2018 May 2. Review.</citation>
    <PMID>29681183</PMID>
  </reference>
  <reference>
    <citation>Hassell KJ, Ezzati M, Alonso-Alconada D, Hausenloy DJ, Robertson NJ. New horizons for newborn brain protection: enhancing endogenous neuroprotection. Arch Dis Child Fetal Neonatal Ed. 2015 Nov;100(6):F541-52. doi: 10.1136/archdischild-2014-306284. Epub 2015 Jun 10. Review.</citation>
    <PMID>26063194</PMID>
  </reference>
  <reference>
    <citation>McAdams RM, Juul SE. Neonatal Encephalopathy: Update on Therapeutic Hypothermia and Other Novel Therapeutics. Clin Perinatol. 2016 Sep;43(3):485-500. doi: 10.1016/j.clp.2016.04.007. Epub 2016 Jun 22. Review.</citation>
    <PMID>27524449</PMID>
  </reference>
  <reference>
    <citation>Parikh P, Juul SE. Neuroprotective Strategies in Neonatal Brain Injury. J Pediatr. 2018 Jan;192:22-32. doi: 10.1016/j.jpeds.2017.08.031. Epub 2017 Oct 12.</citation>
    <PMID>29031859</PMID>
  </reference>
  <reference>
    <citation>Martinello K, Hart AR, Yap S, Mitra S, Robertson NJ. Management and investigation of neonatal encephalopathy: 2017 update. Arch Dis Child Fetal Neonatal Ed. 2017 Jul;102(4):F346-F358. doi: 10.1136/archdischild-2015-309639. Epub 2017 Apr 6.</citation>
    <PMID>28389438</PMID>
  </reference>
  <reference>
    <citation>Massaro AN, Wu YW, Bammler TK, Comstock B, Mathur A, McKinstry RC, Chang T, Mayock DE, Mulkey SB, Van Meurs K, Juul S. Plasma Biomarkers of Brain Injury in Neonatal Hypoxic-Ischemic Encephalopathy. J Pediatr. 2018 Mar;194:67-75.e1. doi: 10.1016/j.jpeds.2017.10.060.</citation>
    <PMID>29478510</PMID>
  </reference>
  <reference>
    <citation>Prempunpong C, Chalak LF, Garfinkle J, Shah B, Kalra V, Rollins N, Boyle R, Nguyen KA, Mir I, Pappas A, Montaldo P, Thayyil S, Sánchez PJ, Shankaran S, Laptook AR, Sant'Anna G. Prospective research on infants with mild encephalopathy: the PRIME study. J Perinatol. 2018 Jan;38(1):80-85. doi: 10.1038/jp.2017.164. Epub 2017 Nov 2.</citation>
    <PMID>29095433</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Ferrara</investigator_affiliation>
    <investigator_full_name>Anna Tarocco</investigator_full_name>
    <investigator_title>Medical Doctor, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>mild neonatal encephalopathy</keyword>
  <keyword>birth asphyxia</keyword>
  <keyword>metabolic acidosis</keyword>
  <keyword>Autophagy</keyword>
  <keyword>Mitophagy</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

